1. Pharmacological ascorbate induces sustained mitochondrial dysfunction.
- Author
-
Carroll RS, Du J, O'Leary BR, Steers G, Goswami PC, Buettner GR, and Cullen JJ
- Subjects
- Animals, Humans, Mice, Carcinoma, Pancreatic Ductal pathology, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases antagonists & inhibitors, Extracellular Signal-Regulated MAP Kinases genetics, Hydrogen Peroxide metabolism, Oxidative Stress drug effects, Phosphorylation, Reactive Oxygen Species metabolism, Signal Transduction drug effects, Xenograft Model Antitumor Assays, Survival Analysis, Female, Antineoplastic Agents pharmacology, Ascorbic Acid pharmacology, Mitochondria drug effects, Mitochondria metabolism, Mitochondria pathology, Mitochondrial Dynamics drug effects
- Abstract
Pharmacological ascorbate (P-AscH
- ; high dose given intravenously) generates H2 O2 that is selectively cytotoxic to cancer compared to normal cells. The RAS-RAF-ERK1/2 is a major signaling pathway in cancers carrying RAS mutations and is known to be activated by H2 O2 . Activated ERK1/2 also phosphorylates the GTPase dynamin-related protein (Drp1), which then stimulates mitochondrial fission. Although early generation of H2 O2 leads to cytotoxicity of cancer cells, we hypothesized that sustained increases in H2 O2 activate ERK-Drp1 signaling, leading to an adaptive response; inhibition of this pathway would enhance the toxicity of P-AscH- . Increases in phosphorylated ERK and Drp1 induced by P-AscH- were reversed with genetic and pharmacological inhibitors of ERK and Drp1, as well as in cells lacking functional mitochondria. P-AscH- increased Drp1 colocalization to mitochondria, decreased mitochondrial volume, increased disconnected components, and decreased mitochondrial length, suggesting an increase in mitochondrial fission 48 h after treatment with P-AscH- . P-AscH- decreased clonogenic survival; this was enhanced by genetic and pharmacological inhibition of both ERK and Drp1. In murine tumor xenografts, the combination of P-AscH- and pharmacological inhibition of Drp1 increased overall survival. These results suggest that P-AscH- induces sustained changes in mitochondria, through activation of the ERK/Drp1 signaling pathway, an adaptive response. Inhibition of this pathway enhanced the toxicity P-AscH- to cancer cells., Competing Interests: Declaration of competing interest The authors declare that they have no conflicts of interest with the contents of this article., (Published by Elsevier Inc.)- Published
- 2023
- Full Text
- View/download PDF